Plague - Pipeline Review, H2 2017 Market Report; Launched via MarketResearchReports.com

Plague - Pipeline Review, H2 2017, provides an overview of the Plague (Infectious Disease) pipeline landscape.

Plague is an infection caused by the bacterium Yersinia pestis. The organism is transmitted to humans who are bitten by fleas that have fed on infected rodents or by humans handling infected animals. Symptoms include headache, fatigue or malaise, muscle aches, fever and chills, abdominal pain, diarrhea and vomiting, shock and bleeding from mouth, nose or rectum, or under skin. Treatment includes antibiotics.

Report Highlights

Plague - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Plague (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Plague (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Plague and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical, Discovery and Unknown stages are 1, 13, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 3 and 1 molecules, respectively.

Plague (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Plague (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Plague (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Plague (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Plague (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Plague (Infectious Disease)

Reasons to buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Plague (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Plague (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Spanning over 81 pages “Plague - Pipeline Review, H2 2017” report covers Introduction, Report Coverage, Plague - Overview, Plague - Therapeutics Development, Plague - Therapeutics Assessment, Plague - Companies Involved in Therapeutics Development, plague (trivalent) vaccine - Drug Profile, Plague - Dormant Projects, Appendix. This report Covered Companies - Achaogen Inc, Aradigm Corp, AvidBiotics Corp, Endacea Inc, GlaxoSmithKline Plc, Grifols SA, iBio Inc, Mucosis BV, Prokarium Ltd, Syntiron LLC, Tetraphase Pharmaceuticals Inc.

Please visit this link for more details: http://mrr.cm/UqN

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

Related Reports;

Male Hypogonadism - Pipeline Review, H2 2017 - Visit at - http://mrr.cm/Uqx

Botulism - Pipeline Review, H2 2017 - Visit at - http://mrr.cm/Uqf